poisar

Stocks · News reference

Teva Pharma And Sanofi Report Duvakitug Maintained Efficacy Through 44 Weeks In Ulcerative Colitis And Crohn's Disease

Benzinga Newsdesk

In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SNYTEVA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

    The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

    ABBVLLYJNJNVSBMY
  2. Delveinsight

    Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

    The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.

    JNJEXELABBVAGENVSTM
  3. Delveinsight

    Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

    Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

    LLYBIIBJNJABBVRHHBY
  4. Na

    GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth

    GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years. The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV.

    GSKAZNMRKSNYGILD
  6. Delveinsight

    Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

    The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

    IPSEYEVMNABBVPFELLY